The molecular background of the Ca2+-sensitizing effect of levosimendan relates to its specific interaction with the Ca2+-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived metabolite, OR-1896. First of all, activation of ATP-sensitive sarcolemmal K+ channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K+ channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. Finally, it has become evident, that levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect. Interpretation of the complex mechanism of levosimendan action requires that all potential pharmacological interactions are analyzed carefully in the framework of the currently available evidence. These data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators

Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan / Papp, Zoltán; Édes, István; Fruhwald, Sonja; De Hert, Stefan G.; Salmenperä, Markku; Leppikangas, Heli; Mebazaa, Alexandre; Landoni, Giovanni; Grossini, Elena; Caimmi, Philippe; Morelli, Andrea; Guarracino, Fabio; Schwinger, Robert H. G.; Meyer, Sven; Algotsson, Lars; Wikström, Bernt Gerhard; Jörgensen, Kirsten; Filippatos, Gerasimos; Parissis, John T.; González, Martín J. García; Parkhomenko, Alexander; Yilmaz, Mehmet Birhan; Kivikko, Matti; Pollesello, Piero; Follath, Ferenc. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - STAMPA. - 159:2(2012), pp. 82-87. [10.1016/j.ijcard.2011.07.022]

Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan

Morelli, Andrea;
2012

Abstract

The molecular background of the Ca2+-sensitizing effect of levosimendan relates to its specific interaction with the Ca2+-sensor troponin C molecule in the cardiac myofilaments. Over the years, significant preclinical and clinical evidence has accumulated and revealed a variety of beneficial pleiotropic effects of levosimendan and of its long-lived metabolite, OR-1896. First of all, activation of ATP-sensitive sarcolemmal K+ channels of smooth muscle cells appears as a powerful vasodilator mechanism. Additionally, activation of ATP-sensitive K+ channels in the mitochondria potentially extends the range of cellular actions towards the modulation of mitochondrial ATP production and implicates a pharmacological mechanism for cardioprotection. Finally, it has become evident, that levosimendan possesses an isoform-selective phosphodiesterase-inhibitory effect. Interpretation of the complex mechanism of levosimendan action requires that all potential pharmacological interactions are analyzed carefully in the framework of the currently available evidence. These data indicate that the cardiovascular effects of levosimendan are exerted via more than an isolated drug-receptor interaction, and involve favorable energetic and neurohormonal changes that are unique in comparison to other types of inodilators
2012
Ca2+-sensitization; Cardioprotection; Levosimendan; Mechanism of action; Positive inotropy; Vasodilation; Animals; Cardiotonic Agents; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hydrazones; Pyridazines; Vasodilator Agents; Consensus; Medicine (all); Cardiology and Cardiovascular Medicine
01 Pubblicazione su rivista::01a Articolo in rivista
Levosimendan: Molecular mechanisms and clinical implications: Consensus of experts on the mechanisms of action of levosimendan / Papp, Zoltán; Édes, István; Fruhwald, Sonja; De Hert, Stefan G.; Salmenperä, Markku; Leppikangas, Heli; Mebazaa, Alexandre; Landoni, Giovanni; Grossini, Elena; Caimmi, Philippe; Morelli, Andrea; Guarracino, Fabio; Schwinger, Robert H. G.; Meyer, Sven; Algotsson, Lars; Wikström, Bernt Gerhard; Jörgensen, Kirsten; Filippatos, Gerasimos; Parissis, John T.; González, Martín J. García; Parkhomenko, Alexander; Yilmaz, Mehmet Birhan; Kivikko, Matti; Pollesello, Piero; Follath, Ferenc. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - STAMPA. - 159:2(2012), pp. 82-87. [10.1016/j.ijcard.2011.07.022]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1087974
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 89
  • Scopus 247
  • ???jsp.display-item.citation.isi??? 220
social impact